A global action agenda for turning the tide on fatty liver disease.
Author
Lazarus, Jeffrey VMark, Henry E
Allen, Alina M
Arab, Juan Pablo
Carrieri, Patrizia
Noureddin, Mazen
Alazawi, William
Alkhouri, Naim
Alqahtani, Saleh A
Anstee, Quentin M
Arrese, Marco
Bataller, Ramon
Berg, Thomas
Brennan, Paul N
Burra, Patrizia
Castro-Narro, Graciela E
Cortez-Pinto, Helena
Cusi, Kenneth
Dedes, Nikos
Duseja, Ajay
Francque, Sven M
Gastaldelli, Amalia
Hagström, Hannes
Huang, Terry T-K
Ivancovsky Wajcman, Dana
Kautz, Achim
Kopka, Christopher J
Krag, Aleksander
Newsome, Philip N
Rinella, Mary E
Romero, Diana
Sarin, Shiv Kumar
Silva, Marcelo
Spearman, C Wendy
Terrault, Norah A
Tsochatzis, Emmanuel A
Valenti, Luca
Villota-Rivas, Marcela
Zelber-Sagi, Shira
Schattenberg, Jörn M
Wong, Vincent Wai-Sun
Younossi, Zobair M
Publication date
2023-08-04
Metadata
Show full item recordAbstract
Background aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over two rounds a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. Priorities were revised between rounds and in R2 panelists also ranked the priorities within six domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2 the mean percentage of 'agree' responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% 'agree'). The highest ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reducing fatty liver disease prevalence and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.Citation
Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Anstee QM, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Gastaldelli A, Hagström H, Huang TTK, Ivancovsky Wajcman D, Kautz A, Kopka CJ, Krag A, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Terrault NA, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM; on behalf of the Healthy Livers, Healthy Lives Collaborators. A global action agenda for turning the tide on fatty liver disease. Hepatology. 2024 Feb 1;79(2):502-523. doi: 10.1097/HEP.0000000000000545. Epub 2023 Aug 4.Type
ArticlePMID
37540183Journal
HepatologyPublisher
Lippincott, Williams & Wilkinsae974a485f413a2113503eed53cd6c53
10.1097/HEP.0000000000000545